skip to Main Content

Exploring the Implications of the Delamanid Phase III and STREAM Trial Results


Note that the following PDFs listed at the top of this page were handouts shared with the Webinar:
–Phase III Clinical Trial Results at the 48th Union World Conference on Lung Health: Implications for the Field1, PDF
–TB CAB’s Proposed Development Pathway for Regimens to Treat Extensively Drug-Resistant Tuberculosis, PDF
–The Devil We Know: Is the Use of Injectable Agents for the Treatment of MDR-TB Justified? PDF

The Results Are In: Now What? Webinar Video

The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) presented the results in a Webinar held on December 12, 2017. We explored implications for the field, from the delamanid C213 trial and the STREAM trial to evaluate the shorter regimen for MDR-TB.

Participants included:

  • Dr. Francesca Conradie, Wits University
  • Dr. Carole Diane Mitnick, Harvard Medical School
  • Marcus Low, Spotlight
  • Mandy Slutsker, ACTION
  • Moderator: Erica Lessem, TAG’s Deputy Executive Director – TB Programs.

Based on the trial results and these discussions, TAG and DR-TB STAT issued the following brief on the shorter regimen:





Back To Top